Financial Performance - The company's operating revenue for Q1 2025 was RMB 229,843,941.53, representing a 3.60% increase compared to RMB 221,850,180.79 in the same period last year[6]. - Net profit attributable to shareholders for Q1 2025 was RMB 58,071,117.89, up 5.20% from RMB 55,199,616.28 year-on-year[6]. - Basic and diluted earnings per share for Q1 2025 were both RMB 0.15, reflecting a 7.14% increase from RMB 0.14 in the same quarter last year[6]. - Operating profit for Q1 2025 was ¥64,486,939.60, compared to ¥59,325,467.29 in Q1 2024, reflecting an increase of approximately 8.3%[24]. - Net profit for Q1 2025, after tax expenses of ¥6,456,361.94, was ¥58,030,577.66, up from ¥55,107,063.21 in Q1 2024[24]. - The net profit for the first quarter of 2025 was CNY 58,030,577.70, an increase from CNY 55,107,063.21 in the same period of 2024, representing a growth of approximately 3.5%[25]. Cash Flow Management - The net cash flow from operating activities improved to RMB -75,343,585.60, compared to RMB -129,613,339.07 in the previous year, indicating better cash management[6][11]. - Cash inflows from operating activities totaled CNY 160,007,655.13 in Q1 2025, down from CNY 217,425,731.31 in Q1 2024, reflecting a decrease of about 26.5%[26]. - Cash outflows from operating activities amounted to CNY 235,351,240.73 in Q1 2025, compared to CNY 347,039,070.38 in Q1 2024, showing a reduction of approximately 32.1%[27]. - The net cash flow from operating activities was negative CNY 75,343,585.60 for Q1 2025, an improvement from negative CNY 129,613,339.07 in Q1 2024[27]. - The net cash flow from investment activities for Q1 2025 was CNY 732,309,135.35, a significant increase from CNY 83,728,306.55 in Q1 2024[27]. - The ending balance of cash and cash equivalents as of the end of Q1 2025 was CNY 1,796,034,364.28, up from CNY 1,220,123,829.78 at the end of Q1 2024[28]. Research and Development - Research and development expenses totaled RMB 26,897,460.32, down 23.13% from RMB 34,991,868.71 year-on-year, with R&D expenses as a percentage of operating revenue decreasing to 11.70% from 15.77%[6][7]. - The company reported a significant increase in research and development expenses, totaling ¥26,897,460.32 in Q1 2025, compared to ¥34,991,868.71 in Q1 2024, indicating a strategic focus on innovation[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 7,182, with 7,167 A-share holders and 15 H-share holders[16]. - The largest shareholder, Shi Chunbao, holds 118,769,747 shares, representing 30.96% of the total shares[16]. - The second-largest shareholder, Yue Shujun, holds 95,447,900 shares, accounting for 24.88% of the total shares[16]. - The company has a total of 17,250,000 shares held by Beijing Panmo Investment Management Co., Ltd., which represents 4.50% of the total shares[15]. - The total number of shares held by the top 10 shareholders includes significant stakes from various investment funds and individuals, with the largest being 118,769,747 shares[16]. - The company has not reported any changes in the lending or borrowing of shares among the top shareholders during the reporting period[16]. Assets and Liabilities - Total assets at the end of Q1 2025 were RMB 3,473,532,404.39, a slight increase of 0.22% from RMB 3,465,734,982.98 at the end of the previous year[7]. - Total liabilities decreased to ¥594,157,689.89 as of March 31, 2025, from ¥644,390,846.18 at the end of 2024, representing a reduction of about 7.8%[21]. - The company’s total equity increased to ¥2,879,374,714.50 as of March 31, 2025, from ¥2,821,344,136.80 at the end of 2024, indicating a growth of approximately 2.1%[21]. Audit and Compliance - The board of directors confirmed the accuracy and completeness of the financial report, ensuring no misleading statements or omissions[5]. - The financial statements are prepared in RMB, and the audit type is unaudited[18]. - The company has not disclosed any significant operational issues or reminders for investors during the reporting period[17].

Financial Performance - In 2024, the company achieved operating revenue of RMB 805.857 million, a year-on-year decrease of 33.32%[10] - The net profit attributable to shareholders was RMB 124.661 million, down 55.01% year-on-year, while the net profit after deducting non-recurring gains and losses was RMB 94.536 million, a decrease of 62.80%[10] - The company's total assets and net assets were RMB 346.573 million and RMB 281.990 million, respectively, representing declines of 5.04% and 2.00% compared to the previous year[10] - The company's operating profit for 2024 was RMB 130.715 million, reflecting a significant decline from previous years[8] - Basic earnings per share were RMB 0.33, down 54.17% year-on-year, with diluted earnings per share also at RMB 0.33[10] - The company's income tax expense for the year ended December 31, 2024, was approximately RMB 69.4 million, a significant decrease from approximately RMB 280.9 million for the same period last year, primarily due to a reduction in profits[38] - The net profit attributable to the shareholders of the parent company for the year ended December 31, 2024, was approximately RMB 1,249.9 million, a decrease of 55.01% compared to approximately RMB 2,778.2 million for the same period last year, mainly due to the implementation of centralized procurement policies leading to price reductions and lower gross margins[39] - The company's cash and cash equivalents decreased from approximately RMB 1,266.37 million as of December 31, 2023, to approximately RMB 1,139.78 million as of December 31, 2024[40] Research and Development - Research and development investment for 2024 was RMB 133.097 million, accounting for 16.52% of operating revenue[12] - The company is committed to continuous innovation and has made significant progress in laboratory construction and product development[12] - The company has been granted 698 domestic intellectual property rights, including 149 invention patents, reflecting its strong innovation capability[16] - The company is committed to increasing R&D resources and hiring more R&D personnel to support ongoing projects in orthopedic robotics and personalized joint prosthetics[60] - The company aims to enhance its innovation capabilities by establishing a product R&D center at the new production base in Daxing, focusing on joint products, spinal products, and trauma products[60] - The company is closely monitoring developments in new technologies, such as biomaterials and drug-device combinations, to stay competitive in the market[58] Market Position and Strategy - The company aims to maintain its leading position in the domestic joint prosthesis market while expanding its orthopedic product line to achieve sustainable growth[19] - The company is focused on expanding its product lines and enhancing its market competitiveness through strategic research and development of new materials and technologies[29] - The company is committed to diversifying its product offerings and exploring advanced technologies to increase its market share in the orthopedic medical device sector[29] - The company plans to enhance its product range by optimizing existing products and investing more resources in new product development, particularly in the orthopedic medical device sector[58] - The company aims to strengthen its industry position in the domestic market and reduce the gap with international leaders by continuously updating and innovating its products[24] Corporate Governance - The board is committed to maintaining high standards of corporate governance, believing it is crucial for protecting shareholder interests and enhancing corporate value[69] - The company emphasizes the importance of transparency and accountability in its governance practices[69] - The board believes that adherence to the corporate governance code has been maintained throughout the reporting period[69] - The company has adopted the "Standard Code" for securities trading by directors and supervisors, confirming compliance for the year ending December 31, 2024[70] - The board consists of four committees: audit, nomination, remuneration, and strategy[161] - The company has established an internal control system that effectively covers all financial and operational management activities, ensuring the safety and integrity of its assets[141] Environmental Sustainability - The company is committed to environmental sustainability, complying with all relevant laws and regulations as of December 31, 2024[130] - The company generated 7.437 tons of titanium production waste, with a waste generation rate of 0.068 kg per RMB 10,000 in output[196] - The company reported a total of 10.773 tons of hazardous waste generated in 2024[196] - Carbon dioxide emissions from direct energy sources amounted to 18.10 tons, while indirect emissions were 3,005.6 tons[196] - The company aims to reduce carbon dioxide emissions from 0.0243 tons per RMB 10,000 in 2020 to 0.0157 tons by 2030, representing a 35% reduction[196] - The company processed 9,846.9 tons of wastewater in 2024, with water usage of 15,915.9 tons, resulting in a water usage rate of 0.146 tons per RMB 10,000 in output[199] - The company plans to decrease water usage from 0.180 tons per RMB 10,000 in 2020 to 0.13 tons by 2030, achieving a 27.8% reduction[199] - The company has established an environmental protection management system to mitigate the impact of its operations on the environment[194] Employee and Shareholder Relations - The total number of employees as of December 31, 2024, is approximately 1,237, with total salary and related costs amounting to RMB 246.88 million[63] - The company has established a retirement benefit plan for eligible employees, with contributions based on a percentage of their salaries[121] - The company encourages shareholders to attend meetings and express their opinions directly to the board[180] - The company has established multiple formal communication channels with shareholders to address inquiries and feedback[180] Risk Management - The board is responsible for risk management and internal control systems, ensuring they are effective in managing business risks[186] - The audit committee assists the board in overseeing the design and implementation of risk management and internal control systems[187] - The company has adopted various risk management procedures to define execution authority across major business processes[187] - Internal control assessments are conducted regularly to identify potential risks affecting the company's operations and financial processes[188] Shareholder Dividends - The company plans to distribute a cash dividend of 0.49 yuan per 10 shares for the 2024 fiscal year, aiming to enhance investor confidence[18] - The company plans to distribute a final dividend of RMB 0.49 per 10 shares for the year ending December 31, 2024, compared to RMB 3.62 per 10 shares for the previous year[64] - The total cash dividend for the year is projected to be RMB 50.52 million, representing 40.42% of the net profit attributable to ordinary shareholders[64] Production and Operations - The company is accelerating the construction of new production bases, including the Daxing Biopharmaceutical Industrial Base and the Weixian production base, with facilities gradually coming into use[24] - The company has three production bases, with the Tongzhou base completed in 2015 and the Daxing and Weixian bases currently under construction[128] - The company has implemented geothermal heat pump air conditioning systems at its production bases, significantly enhancing energy efficiency and environmental benefits[200] - Solar power generation equipment has been extensively installed at the new production base in Daxing, indicating a strong future focus on energy savings[200]

Financial Performance - The company's total revenue for the year ended December 31, 2024, was RMB 805,857,022.19, a decrease of 33.3% compared to RMB 1,208,523,845.88 in 2023[7] - Operating profit for the year was RMB 130,714,693.96, down 57.3% from RMB 305,975,463.53 in the previous year[7] - The company's net profit margin for the year was approximately 16.2%, down from 25.3% in 2023[7] - The total profit for the year ended December 31, 2024, was RMB 131,599,169.07, a decrease of 57.0% compared to RMB 305,905,863.04 in 2023[8] - The net profit attributable to shareholders for 2024 was RMB 124,988,009.59, down 55.0% from RMB 277,824,014.12 in 2023[8] - Basic and diluted earnings per share for 2024 were both RMB 0.33, a decline of 54.2% from RMB 0.72 in 2023[8] - The company's total comprehensive income for 2024 was RMB 124,661,283.50, a decrease of 55.0% from RMB 277,818,116.48 in 2023[8] - The revenue from medical devices for the year ended December 31, 2024, was RMB 805.22 million, a decline of 33.31% compared to RMB 1,207.48 million in 2023[44] Assets and Liabilities - The company's cash and cash equivalents decreased to RMB 1,139,778,517.24 from RMB 1,266,367,522.67, representing a decline of 10%[4] - Accounts receivable dropped significantly to RMB 218,658,632.35 from RMB 405,895,527.39, a reduction of 46.1%[4] - Total liabilities decreased to RMB 644,390,846.18 from RMB 770,325,491.93, a decline of 16.4%[5] - The total assets of the company as of December 31, 2024, were RMB 3,465,734,982.98, down from RMB 3,649,560,924.88 in 2023[6] - The company reported a decrease in retained earnings to RMB 1,208,437,565.70 from RMB 1,267,513,008.25, a decline of 4.6%[6] - The net value of current assets decreased from approximately RMB 2,328.69 million to approximately RMB 2,293.74 million[58] Research and Development - Research and development expenses were RMB 133,096,848.59, a decrease of 15.4% from RMB 157,445,504.26 in the previous year[7] - The company has achieved significant advancements in R&D, focusing on new materials such as porous tantalum and magnesium alloys, and has developed a range of new products including knee and hip joint prosthetics, which have increased its market share in the artificial joint sector[30] - The company is committed to developing a comprehensive one-stop oral ecological solution, with plans for orthodontics, implants, restorations, and maxillofacial surgery[32] - The company emphasizes the integration of production, learning, research, and clinical collaboration in its R&D efforts to ensure products meet market demands and clinical practicality[35] - The company aims to enhance its innovation capabilities and increase R&D resources, focusing on advanced customized orthopedic products and robotic systems[72] Market and Product Development - The company operates primarily in the orthopedic medical device sector, which is experiencing growth due to increasing healthcare demands and an aging population[26] - The company actively participated in the national centralized procurement policy, successfully winning bids for three hip joint product systems and a total knee joint system in May 2024[28] - The company has expanded its product offerings in sports medicine, obtaining multiple registration certificates for products such as 3D printed titanium alloy anchors and non-absorbable anchors, enhancing its clinical application capabilities[31] - The company is strategically diversifying its product lines and enhancing its market share in the orthopedic high-value consumables sector through comprehensive strategic planning[29] - The company plans to enhance its product range by optimizing existing products and investing more resources in new product development, particularly in the orthopedic medical device sector[69] Corporate Governance and Management - The board is committed to maintaining high standards of corporate governance, which is essential for protecting shareholder interests and enhancing corporate value[82] - The company has adopted the standard code of conduct for securities trading by directors and supervisors, confirming compliance for the year ending December 31, 2024[83] - The audit committee has reviewed the consolidated financial statements for the year ending December 31, 2024, prepared by Da Xin Accounting Firm[84] - The company will maintain its existing talent development policies and establish a competitive compensation system to attract high-quality talent[74] Shareholder Information - The company plans to distribute a final dividend of RMB 0.49 per 10 shares, which represents 15.00% of the net profit attributable to ordinary shareholders[77] - The total cash dividend for the year is RMB 50.52 million, accounting for 40.42% of the net profit attributable to ordinary shareholders[77] - The company will hold its annual general meeting on June 26, 2025, for shareholders to vote on relevant matters[79] - The company will suspend H-share transfer registration from July 3 to July 7, 2025, to determine eligibility for the final dividend[81]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 表 明 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 北京市春立正達醫療器械股份有限公司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：1858） 2024年第三季度報告 本公告乃北京市春立正達醫療器械股份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）根據香港聯合交易所有限公司證券上市規則第13.09(2)及13.10B 條以及香港法例第571章證券及期貨條例第XIVA部 刊 發，旨 在 向 本 公 司 股 東 及 公 眾 人 士 提 供 本 公 司 最 新 的 財 務 資 料。本 公 告 亦 同 時 在 上 海 證 券 交 易 所 網 站 發 佈。 茲載列本集團截至2 ...

(0) CHINT! 中期報告 北京市春立正達醫療器械股份有限公司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） 股份代號:1858 nly 2024 * 僅供識別 | --- | --- | --- | |-------|----------------------|-------| | | | | | | | | | | | | | | 目錄 | | | | | | | | 公司資料 | | | | 管理層討論及分析 | | | | 企業管治及其他資料 | | | | 審閱報告書 | | | | 合併資產負債表 | | | | 母公司資產負債表 | | | | 合併利潤表 | | | | 母公司利潤表 | | | | 合併現金流量表 | | | | 母公司現金流量表 | | | | 合併股東權益變動表 | | | | 母公司股東權益變動表 | | | | 財務報表附註 | | 公司資料 | --- | --- | |-----------------------------------------|-- ...

Financial Performance - The company's operating revenue for the six months ended June 30, 2024, was RMB 380.13 million, a decrease of 29.7% compared to RMB 540.71 million for the same period in 2023[9]. - Operating profit for the same period was RMB 82.29 million, down 40.6% from RMB 138.46 million year-over-year[9]. - Net profit attributable to shareholders for the six months ended June 30, 2024, was RMB 79.03 million, a decline of 37.3% from RMB 126.08 million in the previous year[12]. - Basic earnings per share decreased to RMB 0.21 from RMB 0.33, reflecting a 36.4% drop[13]. - The total profit for the six months was RMB 83.07 million, down 40.1% from RMB 138.54 million in the same period last year[9]. - The company's net profit attributable to the parent company for the six months ended June 30, 2024, was RMB 79,026,078.82, compared to RMB 277,824,014.12 in the same period of 2023[22]. - Gross profit for the same period was approximately RMB 271.88 million, down 30.54% from RMB 391.41 million year-on-year[48]. - The company's cash flow from operating activities showed a net outflow of approximately RMB 69.06 million, primarily due to reduced sales receipts compared to the previous year[62]. Assets and Liabilities - As of June 30, 2024, the total assets of Beijing Chunlizhengda Medical Instruments Co., Ltd. amounted to RMB 3,632,906,151.99, a decrease from RMB 3,649,560,924.88 as of December 31, 2023[2]. - The total current assets decreased slightly to RMB 2,993,697,416.93 from RMB 3,005,359,817.46 over the same period[2]. - The total liabilities increased to RMB 813,561,621.26 from RMB 770,325,491.93, indicating a rise of approximately 5.5%[5]. - The company's equity attributable to shareholders decreased to RMB 2,817,641,135.16 from RMB 2,877,466,853.34, reflecting a decline of about 2.1%[8]. - The company's retained earnings decreased to RMB 1,207,687,290.07 from RMB 1,267,513,008.25, a decline of approximately 4.7%[7]. - The company reported a total equity of RMB 2,819,344,530.73 as of June 30, 2024, down from RMB 2,879,235,432.95[8]. - The total current liabilities increased to RMB 720,211,490.68 from RMB 676,672,835.51, representing an increase of about 6.4%[4]. Research and Development - Research and development expenses amounted to RMB 67.66 million, a decrease of 9.5% from RMB 74.57 million in the prior year[9]. - The company is focusing on the development of new products and technologies to improve competitiveness in the orthopedic medical device market[34]. - The company will establish a product R&D center at its new production base, focusing on joint products, spinal products, and trauma products, while increasing R&D personnel to enhance innovation capabilities[69]. - The company is actively involved in R&D projects funded by government initiatives, including projects related to orthopedic surgical navigation systems and biodegradable materials[42]. - The company emphasizes collaboration with clinical experts to ensure that its R&D products meet market demands and clinical practicality[42]. Market and Product Development - The company is actively expanding its product lines in orthopedics, including new materials and technologies such as titanium alloys, magnesium alloys, and PEEK[35]. - The company has successfully launched new products in the artificial joint sector, including bone reconstruction rods and tantalum metal fillers, enhancing its market share[36]. - The company has enriched its sports medicine product line with several new registrations, marking a significant advancement in this field[37]. - The company has developed the first domestically produced orthopedic handheld robot systems, improving surgical precision and promoting minimally invasive techniques[38]. - The company has obtained CE certificates for its hip, knee, and spine product lines, and received FDA 510(K) approval for its knee prosthesis system on April 15, 2024, indicating its international market competitiveness[39]. Corporate Governance and Financial Management - The company maintains high standards of corporate governance to protect shareholder interests and enhance corporate value[76]. - The company has adopted the "Standard Code" for securities trading by directors and supervisors, confirming compliance as of June 30, 2024[77]. - The audit committee has reviewed the consolidated financial statements for the six months ending June 30, 2024[78]. - The company is committed to maintaining liquidity through effective management of its financial resources[64]. - The company plans to continue its investment strategy focusing on structured deposit products[65]. Employee and Compensation - The company employs approximately 1,291 employees as of June 30, 2024, with total employee compensation and related costs amounting to approximately RMB 151.56 million[72]. - The company's management expenses increased by 12.39% to approximately RMB 21.31 million from RMB 18.96 million, primarily due to rising employee compensation and rental costs[50]. Dividend and Shareholder Returns - A cash dividend of RMB 0.83 per 10 shares (before tax) is proposed, amounting to a total cash dividend of RMB 31,817,332.47, which represents 40.26% of the net profit attributable to shareholders[75]. - The profit distribution proposal has been approved by the board and will be submitted for approval at the 2024 extraordinary general meeting[75].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 表 明 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 北京市春立正達醫療器械股份有限公司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：1858） 2024年第一季度報告 本公告乃北京市春立正達醫療器械股份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）根據香港聯合交易所有限公司證券上市規則第13.09(2)及13.10B 條以及香港法例第571章證券及期貨條例第XIVA部 刊 發，旨 在 向 本 公 司 股 東 及 公 眾 人 士 提 供 本 公 司 最 新 的 財 務 資 料。本 公 告 亦 同 時 在 上 海 證 券 交 易 所 網 站 發 佈。 茲載列本集團截至2 ...

Financial Performance - In 2023, the company achieved operating revenue of RMB 1,208.52 million, a year-on-year increase of 0.58%[9]. - The net profit attributable to shareholders of the listed company was RMB 277.82 million, a decrease of 9.72% year-on-year[9]. - The basic earnings per share were RMB 0.72, reflecting a decline of 10.00% year-on-year[9]. - The company's gross profit decreased by 4.12% from approximately RMB 913.53 million in 2022 to approximately RMB 875.89 million in 2023, with a gross profit margin dropping from 76.03% to 72.48%[29]. - The company's net profit decreased from approximately RMB 307.72 million in 2022 to approximately RMB 277.82 million in 2023, primarily due to the impact of national procurement policies on product pricing[32]. - The total comprehensive income for the year was RMB 277,818,116.48, down from RMB 307,719,145.65 in the previous year[192]. - The company reported an investment income of RMB 12,012,452.06, significantly up from RMB 6,748,241.12 in the previous year[191]. - The operating profit decreased to RMB 305,975,463.53, down 6.9% from RMB 328,908,764.68 in the prior year[191]. Assets and Liabilities - The total assets of the company reached RMB 3,649.56 million, an increase of 7.03% compared to the end of the previous year[9]. - The total equity attributable to shareholders of the listed company was RMB 2,877.47 million, an increase of 5.80% year-on-year[9]. - The company's cash and cash equivalents increased by 32.30% from approximately RMB 957.19 million in 2022 to approximately RMB 1,266.37 million in 2023, mainly due to increased customer payments[33]. - Total liabilities increased to RMB 770,325,491.93 from RMB 690,066,911.19, reflecting a growth of approximately 11.6%[186]. - The company's retained earnings increased to RMB 1,267,513,008.25 from RMB 1,136,732,358.10, marking a growth of about 11.5%[187]. Research and Development - In 2023, the company's R&D investment reached CNY 157,445,504.26, accounting for 13.03% of its operating revenue[11]. - The company is actively involved in national key R&D projects, including the development of porous tantalum bone repair materials and clinical applications[13]. - The company is expanding its research and development capabilities by establishing a product R&D center at its new production base in Daxing, focusing on joint products, spinal products, and trauma products[48]. - The company is committed to continuous product innovation and aims to narrow the gap with international leaders in the orthopedic sector, aspiring to become a world-class orthopedic innovation enterprise[23]. Market Strategy and Expansion - The company aims to maintain its leading position in the domestic joint prosthesis market and increase its market share while expanding its orthopedic product line[18]. - The company accelerated the development of new products and expanded its domestic and international market share[8]. - The company adopted a multi-channel marketing strategy, including offline distribution and direct sales, to promote its products domestically[10]. - The company plans to enhance its market share by seeking advanced technologies and excellent products in related orthopedic fields[26]. - A strategic plan to enter the Southeast Asian market is underway, with an initial investment of $5 million allocated for market research and local partnerships[60]. Corporate Governance - The company emphasizes the importance of governance structure and internal control effectiveness, having revised the Independent Director Work System in 2023 to align with regulatory requirements[20]. - The company aims to improve investor relations by enhancing information disclosure quality and maintaining transparent communication through various channels, thereby establishing a positive corporate image in the capital market[21]. - The board of directors consists of eight members, including four executive directors, one non-executive director, and three independent non-executive directors, complying with listing rules[107]. - The company has adopted a standard code for securities trading by directors and supervisors, confirming compliance for the year ended December 31, 2023[58]. Environmental and Social Responsibility - The company has implemented a comprehensive environmental management system to minimize its impact on natural resources and comply with relevant environmental laws[149]. - The company aims to reduce electricity consumption from 60.9 kWh per RMB 10,000 in 2020 to 43 kWh by 2030, achieving a 29.4% decrease[154]. - The company has established a whistleblowing procedure for employees to report concerns regarding criminal offenses or financial misconduct[145]. - The company has been actively involved in community investment, donating over CNY 100,000 in flood relief materials in 2023[168]. Employee Management - The company has approximately 1,231 employees as of December 31, 2023, with total salary and related costs amounting to RMB 233.87 million for the year[51]. - The company continues to implement a talent development policy and has established an effective incentive mechanism to motivate employees[50]. - The turnover rate for employees under 30 years old was 36.48%, significantly higher than other age groups[155]. - The training completion rate for new employees was 100%, with an average training duration of 137 hours[158]. Future Outlook - The company projects a revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion strategies[60]. - The company plans to enhance its capital operation channels and improve its risk resistance through active communication in the capital market[16]. - The company aims to enhance its research and development capabilities for new technologies[199]. - The company is exploring potential mergers and acquisitions to strengthen its market position[199].

Financial Performance - The company's total revenue for the year ended December 31, 2023, was RMB 1,208,523,845.88, a slight increase from RMB 1,201,604,254.24 in 2022, representing a growth of approximately 0.2%[6]. - Operating profit for 2023 was RMB 305,975,463.53, down from RMB 328,908,764.68 in 2022, indicating a decrease of about 7%[6]. - Net profit for the year was RMB 277,818,116.48, compared to RMB 307,719,145.65 in the previous year, reflecting a decline of approximately 9.7%[7]. - The company's gross profit decreased by 4.12% from approximately RMB 913.53 million in 2022 to approximately RMB 875.89 million in 2023, with a gross profit margin dropping from 76.03% to 72.48%[51]. - The basic earnings per share for 2023 was RMB 0.72, down from RMB 0.80 in 2022, indicating a decrease of 10%[8]. - The company's net profit decreased from approximately RMB 307.72 million for the year ended 2022 to approximately RMB 277.82 million for the year ended 2023, primarily due to the impact of national high-value consumables procurement policies and a decline in product prices[58]. Assets and Liabilities - The total assets of Beijing Chunlizhengda Medical Instruments Co., Ltd. as of December 31, 2023, amounted to RMB 3,649,560,924.88, an increase from RMB 3,409,766,690.91 in 2022, representing a growth of approximately 7%[2]. - The company's current assets reached RMB 3,005,359,817.46, up from RMB 2,779,088,982.86 in the previous year, indicating an increase of about 8.1%[2]. - The total liabilities as of December 31, 2023, were RMB 770,325,491.93, compared to RMB 690,066,911.19 in 2022, reflecting a rise of approximately 11.6%[4]. - The equity attributable to shareholders increased to RMB 2,877,466,853.34 from RMB 2,719,699,779.72, marking a growth of around 5.8%[5]. - The company's cash and cash equivalents rose to RMB 1,266,367,522.67, compared to RMB 957,193,661.02 in the previous year, representing an increase of approximately 32.3%[2]. - The total accounts payable as of December 31, 2023, was RMB 225,500,169.91, a decrease from RMB 237,786,563.39 in 2022, representing a decline of about 5.2%[20]. Research and Development - The company has invested in new product development and technology, although specific figures were not disclosed in the conference call[1]. - Research and development expenses amounted to RMB 157,445,504.26 in 2023, slightly lower than RMB 162,340,798.73 in 2022, showing a decrease of about 3.5%[6]. - The company is focusing on R&D of new materials such as titanium, magnesium alloy, and PEEK, as well as new product lines in robotics and sports medicine[35]. - The R&D team consists of professionals with over 10 years of experience, including PhD researchers, ensuring strong innovation capabilities[42]. - The company has undertaken multiple key R&D projects, including the development of high-quality medical metal powder materials and biodegradable medical magnesium alloy materials[43][44]. Market and Product Development - The orthopedic implant market has seen significant growth due to factors such as an aging population and increased healthcare spending in China[34]. - The company aims to enhance its market share in the orthopedic sector while expanding into related fields such as spine and trauma products[36]. - The company has successfully registered multiple new products in the orthopedic field, including 3D printed hip prostheses and high-performance polyethylene hip and knee products, filling market gaps and increasing market share[37]. - The company has entered the dental field with multiple product registrations, including orthodontic and maxillofacial products, marking its official entry into this market[38]. - The company has developed and launched a fully automated platelet-rich plasma preparation system, becoming the first in China to do so, indicating its progress in the field of source equipment[39]. Corporate Governance and Compliance - The company has adhered to all applicable principles and code provisions of corporate governance as of December 31, 2023[85]. - The company has adopted the standard code for securities trading by directors and has confirmed compliance for the year ending December 31, 2023[86]. - The audit committee has reviewed the consolidated financial statements for the year ending December 31, 2023[87]. Future Outlook - Future outlook includes plans for market expansion and potential mergers and acquisitions to enhance growth opportunities[1]. - The company aims to transition from a domestic leader in artificial joints to a comprehensive orthopedic enterprise covering multiple specialized fields, including joints, spine, trauma, and sports medicine[40]. - The company plans to enhance its product offerings by investing more resources in R&D for new products, focusing on joint prosthetics and expanding into new markets[74].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 表 明 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 北京市春立正達醫療器械股份有限公司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：1858） 2023年第三季度報告 本公告乃北京市春立正達醫療器械股份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）根據香港聯合交易所有限公司證券上市規則第13.09(2)及13.10B 條以及香港法例第571章證券及期貨條例第XIVA部 刊 發，旨 在 向 本 公 司 股 東 及 公 眾 人 士 提 供 本 公 司 最 新 的 財 務 資 料。本 公 告 亦 同 時 在 上 海 證 券 交 易 所 網 站 發 佈。 茲載列本集團截至2 ...